Last reviewed · How we verify

NCT05164289: EMDRpsychose

Interest of EMDR Schizophrenic Disorders

Terminated Last updated 19 September 2024
What this trial tests

trial testing Control group in Schizophrenic Disorders in 6 participants. Terminated before completion.

Timeline
10 December 2021
Primary endpoint
27 April 2022
27 April 2022

Quick facts

Lead sponsorHôpital NOVO
StatusTerminated
Study typeOBSERVATIONAL
Enrollment6
Start date10 December 2021
Primary completion27 April 2022
Estimated completion27 April 2022
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital NOVO — full company profile →

Who can join

18 and older, any sex, with Schizophrenic Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Control group

Trials testing the same drug.

Other Hôpital NOVO trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05164289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing